Journal
CURRENT OPINION IN IMMUNOLOGY
Volume 40, Issue -, Pages 14-23Publisher
CURRENT BIOLOGY LTD
DOI: 10.1016/j.coi.2016.02.008
Keywords
-
Categories
Ask authors/readers for more resources
The clinical success of Adcetris (R) (brentuximab vedotin) and Kadcyla (R) (ado-trastuzumab emtansine) has sparked clinical development of novel ADCs. These powerful anti-cancer agents are designed to allow specific targeting of highly potent cytotoxic agents to tumor cells while sparing healthy tissues. Despite the use of tumor-specific antibodies, the emerging clinical data with ADCs indicates that adverse effects frequently occur before ADCs have reached their optimal therapeutic dose, resulting in a relatively narrow therapeutic window. This review summarizes the therapeutic window of ADCs currently in clinical development, along with some strategies that may help to widen the window.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available